A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

NCT03957590 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Tislelizumab
DRUG: Placebo
DRUG: Paclitaxel
DRUG: Cisplatin
RADIATION: Radiotherapy

Sponsor

BeiGene